Sanofi Ventures has assembled a team of individuals combining not only investor backgrounds but also entrepreneurial experiences in biotech and digital companies.


Jim Trenkle
Head of Investments


Jim joined Sanofi Ventures in 2020 with a background in R&D, commercialization, and early stage biotech investing and transactions. Prior to joining Sanofi, Jim was Vice President of Investments with Pivotal bioVenture Partners in San Francisco where he was board observer for several portfolio companies. Previous to Pivotal, Jim began his career with Gilead Sciences in 2007 where he held positions of increasing responsibility in medicinal chemistry, project and portfolio management, and commercial strategy, largely focused on hepatitis C and other liver diseases.

Jim currently serves as a board observer for Inozyme Pharma and Yumanity Therapeutics.

Jim completed a BS in Honors Chemistry at University of Michigan, PhD in Organic Chemistry at Massachusetts Institute of Technology and holds an MBA from University of California Berkeley, Haas School of Business.

Cris De Luca
Global Head of Digital Investments


Cris joined Sanofi Ventures in 2020 with a 15+ year track record of building and launching emerging technologies, startups and innovation platforms for some of the largest organizations in the world. Prior to Sanofi, Cris was a founding team member of J&J Innovation and Global Head of Digital Innovation since 2013. He held primary digital and data responsibilities, driving strategy and external tech collaborations throughout J&J’s Innovation Centers, JLABS incubators and JJDC corporate ventures across the Pharmaceutical, Consumer and Medical Device businesses.

Previously, Cris led emerging technology programs within research informatics at Novartis Institutes for BioMedical Research for six years. With entrepreneurial DNA, Cris is well recognized for his role in the innovation economy since Co-Founding one of the largest startup venture pitch accelerators in the U.S called Ultra Light Startups, accelerating hundreds of companies in Boston, New York City and Silicon Valley, with several large-scale acquisitions by major tech companies. Cris was named a 40 under 40 Innovator by the Boston Business Journal in 2015, and Top 40 Healthcare Transformer by MM&M Magazine in 2019.

Cris currently serves on the boards of Medisafe, Click Therapeutics, Omada Health, and Aetion. He is also on the advisory boards of the American Telemedicine Association, SXSW Health, Voice by Amazon Alexa and the Boston University SPH Innovation Hub.

Cris holds a MSc in Computer Information Systems from Boston University and a BS in Business Administration from Suffolk University

Jason P. Hafler
Managing Director


Jason joined Sanofi Ventures in 2014 with a background in early stage biotech investing and transactions. Prior to Sanofi, Jason was the Director of Corporate Development at RaNA Therapeutics, LLC a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group and a Board Observer for several portfolio companies. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space.

Jason currently serves on the Board of Directors for Escient Pharmaceuticals, Icosavax, Expansion Therapeutics and Amathus Therapeutics and is a board observer for Q32 Bio, Navitor Pharmaceuticals and Kymera Therapeutics. Jason also serves on the Board of Trustees at the Buckingham Browne and Nichols school, the Board of Directors of The Magdalene College Foundation and the Board of Directors of the Beacon Hill Nursery School.

Jason graduated with honors from Bowdoin College, and holds a Ph.D. from the University of Cambridge.

Christopher Gagliardi
Director of Investments


Chris joined Sanofi Ventures in 2017 with a background in life science and healthcare consulting. He previously spent three years as a management consultant at LEK consulting where his work focused on corporate strategy, due diligence, commercial launch planning and asset valuation across the pharmaceutical, biotech, R&D and API manufacturing sectors.

Chris currently serves on the Board of Directors for i2O Therapeutics and Minervax.

Prior to a postdoctoral fellowship at Harvard University, Chris earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill as well as a BS in both Biology and Chemistry from Roger Williams University.

Daniel Mansuri
Associate Director


Daniel joined Sanofi Ventures in 2018. He began his career as a member of Biogen's corporate strategy group. He then joined Bioverativ as a member of their BD organization, most recently as Business Development Lead, where he played an important role in both their acquisition of True North Therapeutics and their research collaboration with Bicycle Therapeutics. Given the recent acquisition, we are fortunate to benefit from Daniel’s expertise in the rare hematology and complement space.

Daniel graduated with honors from Bates College with a Bachelor of Science in Economics and a minor in Chemistry.

Laia Crespo, EU
Head of Investments


Laia joined Sanofi Ventures in 2018 with a background in biotech investing primarily in Europe. Prior to Sanofi, Laia served as Investment Director for Ysios Capital, a Venture fund based in Barcelona, where she led investments and served on the Boards of OxThera (Sweden), Minoryx Therapeutics (Spain) and Inbiomotion (Spain), and as an Observer with AM-Pharma (The Netherlands). Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group, where she assessed commercial and scientific licensing-in opportunities. Previously she worked as a researcher in the UK in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech.

Laia currently serves on the Board of Directors for Lava Therapeutics and is board observer for Nodthera Therapeutics.

Laia graduated in Chemistry from the University of Barcelona, where she also completed a Master in Science and a PhD with honors. Laia holds an MBA from Cambridge Judge Business School, University of Cambridge, where she focused on biotechnology, healthcare and finance.

Robin Smick
Executive Assistant


Robin joined Sanofi Ventures in 2018 with a background in administrative medical affairs at Sanofi since 2013. Prior to Sanofi, Robin was the Head of Administration at MIT Bates Research & Engineering Center for five years. Robin also spent 10 years conducting property and business valuations for variety of companies.

Robin studied Business administration and finance at Salem State University.